Phargentis begins clinical development of early-entry generic version of COPD treatment indacaterol/glycopyrronium and DPI device
(16 December, 2021) Phargentis has begun clinical development of its capsule based DPI (Dry Powder Inhaler) product containing indacaterol/glycopyrronium (85 mcg/43 mcg) designed to be an early-entry, fully interchangeable generic version of the global COPD treatment Ultibro®Breezhaler®. Sales of the treatment exceed 500 MUSD a year. The news follows the recent announcement of the company’s first European sales of its generic Tiotropium bromide Dry Powder Inhaler. CEO Andrea Tam: “We are delighted to enter the clinical phase of development in this vital, highly effective product.”Phargentis